文献速递神经免疫

丹麦全国性AQP4抗体阳性视神经脊髓炎谱系疾病患者队列的死亡率

Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort.
PubMed 文献 · Neurology · 2024-02-06

该研究纳入丹麦2008至2020年66例符合2015年IPND标准的AQP4抗体阳性视神经脊髓炎谱系疾病患者,与年龄、性别和日历年匹配的普通人群比较,发现患者死亡率升高、预期寿命缩短,93%的死亡直接与疾病相关。

要点

  • AQP4抗体阳性视神经脊髓炎谱系疾病患者死亡风险约为匹配普通人群的2.22倍(HR 2.22)。
  • 患者中位预期寿命为64.08岁,普通人群为83.07岁。
  • 93%的死亡直接与视神经脊髓炎谱系疾病相关,发病年龄是死亡的独立预测因素。

核心结论

  • 与普通人群相比,AQP4抗体阳性视神经脊髓炎谱系疾病与死亡率升高和预期寿命缩短相关,强调需要高效治疗方法。

研究设计与样本

  • 从多个来源(实验室和丹麦多发性硬化登记处)识别2008年至2020年符合2015年国际视神经脊髓炎诊断小组(IPND)标准的AQP4抗体阳性视神经脊髓炎谱系疾病患者66例,从医院记录获取患者详细信息,并从丹麦统计局获取按年龄、性别和日历年匹配的普通人群信息。

主要发现

  • 66例患者中15例死亡,标准化死亡比为2.54(95%CI 1.47-4.09),每1000人年超额死亡数为16.8(95%CI 4.6-34.3)。
  • 患者中位预期寿命为64.08岁(95%CI 53.02-83.9),匹配普通人群为83.07岁。
  • 患者死亡风险随时间增加,风险比为2.22(95%CI 1.34-3.68;p=0.002)。
  • 93%的死亡病例直接与视神经脊髓炎谱系疾病相关。
  • 发病年龄是死亡的独立预测因素(HR 1.042;95%CI 1.006-1.079;p=0.02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: We aimed to evaluate the mortality of patients with AQP4 antibody-seropositive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) in Denmark compared with that in the general population. METHODS: We identified patients with AQP4-Ab+ NMOSD fulfilling the 2015 International Panel for Neuromyelitis Optica Diagnosis (IPND) criteria from multiple sources (laboratories and the Danish Multiple Sclerosis Registry). We obtained detailed information about patients from hospital records and about the general population matched on age, sex, and calendar year from Statistics Denmark. We calculated standardized mortality ratio (SMR), excess number of deaths per 1,000 person-years (EDR), and life expectancies compared with those of the matched general population. We examined predictive factors of mortality and the cause of death. RESULTS: Of 66 patients with AQP4-Ab+ NMOSD between 2008 and 2020, 15 died. Overall, the SMR was 2.54 (95% CI 1.47-4.09), and the EDR was 16.8 (95% CI 4.6-34.3). The median life expectancy for patients with AQP4-Ab+ NMOSD was 64.08 years (95% CI 53.02-83.9), compared with 83.07 years for the general population. Risk of death over time was increased in the patient population with a hazard ratio (HR) of 2.22 (1.34-3.68; p = 0.002). The cause of death was directly related to NMOSD in 93% of the cases. The age at disease onset was an independent predictor of death (HR 1.042; 95% CI 1.006-1.079; p = 0.02). DISCUSSION: AQP4-Ab+ NMOSD is associated with increased mortality and shorter life expectancy compared with that in the general population, underlining the need for highly effective treatment approaches.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Papp V, Magyari M, Möller S, et al. Mortality of the Danish Nationwide AQP4 Antibody-Seropositive Neuromyelitis Optica Spectrum Disorder Patient Cohort. Neurology. 2024. PMID: 38546185. doi:10.1212/WNL.0000000000209147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。